Barclays
LAB icon

Barclays’s Standard BioTools LAB Stock Holding History

Barclays’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-70,000
Closed -$524K – 7137
2018
Q3 		$524K Buy
+70,000
New +$498K ﹤0.01% 4234

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Barclays's LAB Position: Q2 2026 in Review

Barclays reduced its Standard BioTools (LAB) stake by 98% in Q2 2026, selling an estimated $2.43M and leaving 43,919 shares worth $36.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4428.

Barclays first reported a position in LAB in Q2 2013 and has held it in 48 quarters since. The position peaked at $10.7M in Q1 2024. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Barclays held 43,919 shares of Standard BioTools worth $36.1K as of Q2 2026.
  • Barclays sold 2,574,050 Standard BioTools shares in Q2 2026, an estimated $2.43M.
  • Standard BioTools made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4428 holding.
  • Barclays first reported a position in Standard BioTools in Q2 2013 and has held it in 48 quarters since.
  • Barclays's Standard BioTools position peaked at $10.7M in Q1 2024.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.